Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New suction tool aims to zap kidney stones faster and cleaner

NCT ID NCT07181759

Disease control Sponsor: Ningbo No. 1 Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares a new surgical tool called VISOR to a standard scope for removing kidney stones. VISOR combines suction, pressure control, and laser to break up and remove stones in one step. About 100 adults with stones up to 3 cm will be randomly assigned to get either VISOR or standard surgery. The main goal is to see if VISOR leaves fewer stone fragments right after surgery and at 3 months, while keeping the kidney safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VISOR system (a surgical device that suctions stones and controls pressure during ureteroscopy)
What this could lead to
If it works, this could mean fewer leftover stone fragments and fewer complications for people undergoing kidney stone surgery.
What could go wrong
This is a small, early-stage trial with only 100 people, so results may not apply to everyone. The new device could also cause unexpected side effects like injury or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with upper urinary tract stones and a cumulative stone diameter ≤3 cm; * Patients scheduled to undergo "flexible ureteroscopic holmium laser lithotripsy"; * Age ≥18 years; * Patients without psychiatric disorders or language dysfunction, capable of understanding the study and providing informed consent. Exclusion Criteria: * Patients requiring bilateral lithotripsy in a single-stage ureteroscopic procedure; * Ipsilateral hydronephrosis with \>4 cm renal pelvic separation; * Patients with a history of open or laparoscopic renal and/or ureteral surgery; * Fever (body temperature ≥38°C) due to urinary tract infection or other causes within one week prior to surgery; * Pregnant women; * Patients with severe systemic diseases, cardiac diseases, pulmonary insufficiency, or vital organ failure unable to tolerate anesthesia or surgery (ASA score ≥3); * Patients with anatomical abnormalities such as polycystic kidney, horseshoe kidney, or ectopic kidney; * Patients with coagulation disorders (e.g., INR \>2.0 or platelet count \<80×10⁹/L); * Patients currently participating in other device or drug clinical trials; * Patients deemed ineligible for the trial by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intraoperative complications are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Intraoperative Complications nephrolithiasis Nephrolithiasis, Calcium Oxalate urolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intraoperative complications Therapeutic irrigation Ureteroscopy Urolithiasis, calcium oxalate

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.